Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Pivekimab-sunirine"

3 News Found

AbbVie seeks FDA approval for Pivekimab Sunirine to treat rare, aggressive blood cancer
Drug Approval | October 01, 2025

AbbVie seeks FDA approval for Pivekimab Sunirine to treat rare, aggressive blood cancer

BPDCN is a challenging blood cancer with characteristics of both leukemia and lymphoma

AbbVie showcases broad blood cancer pipeline at EHA 2026 with 21 presentations
Clinical Trials | June 09, 2026

AbbVie showcases broad blood cancer pipeline at EHA 2026 with 21 presentations

The company will present 21 oral and poster presentations spanning investigational and approved therapies

AbbVie wins FDA nod for DECNUPAZ in rare blood cancer
News | May 29, 2026

AbbVie wins FDA nod for DECNUPAZ in rare blood cancer

BPDCN typically presents with skin lesions before rapidly spreading to the bone marrow, lymph nodes

Upcoming E-conference
June 19, 2026 The Future of Clinical Research in India: Can India Become a Global Trial Hub?
July 17, 2026 Biosimilars & Biologics: The Next Growth Frontiers for Indian Pharma

Latest Stories

Centre intensifies push for zero leprosy transmission

India validates first indigenous HPV DNA test for cervical cancer screening

Ryvu advances romaciclib program as FDA clears AML trial expansion

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Our D2 lamp portfolio caters to entire spectrum of chromatography and spectroscopy customers: Hemang Jhaveri, Partner, Hiten Techno Products Corporation
Our D2 lamp portfolio caters to entire spectrum of chromatography and spectroscopy customers: Hemang Jhaveri, Partner, Hiten Techno Products Corporation
From bench to work flow, we are an integrated solution provider: K.O. Satish, Associate Vice President, Spinco Biotech
From bench to work flow, we are an integrated solution provider: K.O. Satish, Associate Vice President, Spinco Biotech
Our vision is to make genomics as commonplace as BP monitor: Dr. Ramesh Hariharan, Chief Executive Officer, Strand Life Sciences
Our vision is to make genomics as commonplace as BP monitor: Dr. Ramesh Hariharan, Chief Executive Officer, Strand Life Sciences
Dr. Ramesh Hariharan Chief Executive Officer, Strand Life Sciences

Packaging